




| | | |
|--|--|---|
| <p>ISSUE DATE</p> <p>June 20, 2023</p> | <p>EFFECTIVE DATE</p> <p>March 14, 2023</p> | <p>NUMBER</p> <p>01-23-08, 05-23-07, 08-23-10, 09-23-07, 10-23-06, 24-23-07, 26-23-06, 30-23-05, 31-23-08, 33-23-07</p> |
| <p>SUBJECT</p> <p>MA Program Fee Schedule Update for an Additional Bivalent Dose of the SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc.</p> | | <p>BY</p>  <p>Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs</p> |

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) added Current Procedural Terminology (CPT) code 0174A to the MA Program Fee Schedule for the administration of an additional bivalent dose of the novel coronavirus (SARS-CoV-2) vaccine manufactured by Pfizer, Inc.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, physician assistants, outpatient hospital-based clinics, independent medical/surgical clinics, federally qualified health centers (FQHC), rural health clinics (RHC), home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines to MA beneficiaries in the Fee-for-Service (FFS) or managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND/DISCUSSION:

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:
<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>.

On March 14, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer, Inc. SARS-CoV-2 vaccine to allow for an additional bivalent dose of the vaccine. Additionally, the American Medical Association (AMA) established a new CPT code 0174A for the administration of the additional bivalent dose of the SARS-CoV-2 vaccine manufactured by Pfizer, Inc. The code is distinct to the additional bivalent dose of the Pfizer, Inc. SARS-CoV-2 vaccine. In response, the Department added CPT code 0174A to the MA Program Fee Schedule, which may be used for dates of service on and after March 14, 2023.

The CPT code 0174A is to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

PROCEDURE:

MA providers in both the FFS and managed care delivery systems are to bill for the administration of the additional bivalent dose of the SARS-CoV-2 vaccine to MA beneficiaries using the CPT code below.

| Vaccine Manufacturer | Code | Code Description | Effective Date |
|-----------------------------|-------------|--|-----------------------|
| Pfizer, Inc. | 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose | 3/14/23 |

NOTE: Provider type 10, specialty 100 (physician assistant) is included because physician assistants can be listed as the rendering provider pursuant to MA Bulletin 01-22-05, 08-22-05, 09-22-04, 10-22-01, 31-22-05, entitled “Billing Procedure Update for Certified Registered Nurse Practitioners and Physician Assistants.”
<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022010701.pdf>.

Attached is the “MA Program Fee Schedule Update for an Additional Bivalent Dose of the SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc., Effective March 14, 2023.” The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, effective date, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

FQHCs and RHCs are to bill with the applicable CPT code, as set forth above when a SARS-CoV-2 vaccine is administered to a MA beneficiary, and no other services that constitute an encounter are rendered on that date. When the SARS-CoV-2 vaccine is

administered during a visit that is a billable encounter, FQHCs and RHCs are to bill procedure code T1015 to be paid their provider-specific Prospective Payment System rate and include the appropriate SARS-CoV-2 vaccine CPT code on a separate claim line for tracking purposes, with no additional payment made for the administration of the vaccine. FQHCs and RHCs may not bill the Department for, or include on their cost report, SARS-CoV-2 vaccines they receive at no cost. FQHCs and RHCs may also not bill for the administration of the vaccine for which they will be paid by another entity to administer.

MA providers who administer a SARS-CoV-2 vaccine to an MA beneficiary who is homebound should bill procedure code M0201 along with the applicable SARS-CoV-2 dose administration code. For additional information related to billing for the administration of SARS-CoV-2 vaccines to an MA beneficiary who is homebound, providers should refer to MA Bulletin 01-21-04, "SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound" for billing instructions. The bulletin may be accessed at the link below: <https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2021072901.pdf>. For additional information related to FQHCs and RHCs billing for the administration of SARS-CoV-2 vaccines to an MA beneficiary who is homebound, providers should refer to MA Bulletin 08-20-68, "Federally Qualified Health Center and Rural Health Clinic Payment for SARS-CoV-2 Vaccine Administration" for billing instructions. The bulletin may be accessed at the link below: <https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022061001.pdf>.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at: <https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code (NDC) and the units dispensed for the vaccine. Providers may access the DHS Pharmacy Services Covered Drugs Search Tool on the Department's website at: <https://www.humanservices.state.pa.us/CoveredDrugs/CoveredDrugs/Index>.

Providers may not bill the MA Program for a SARS-CoV-2 vaccine they receive at no cost or for the administration of a SARS-CoV-2 vaccine for which they will be paid by another entity to administer.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists", issued December 30, 2020, at the link below: <https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2020123001.pdf>.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association - <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.
- Centers for Disease Control and Prevention
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>.
- Centers for Medicare & Medicaid Services
<https://www.medicare.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html>.
- PA Department of Health
<https://www.health.pa.gov/Pages/default.aspx>.

ATTACHMENT:

MA Program Fee Schedule Update for an Additional Bivalent Dose of the SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc., Effective March 14, 2023

MA Program Fee Schedule Update for an Additional Bivalent Dose of the SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc., Effective March 14, 2023

| Procedure Code | National Code Description | Provider Type | Provider Specialty | Place of Service | Pricing Modifier | Informational Modifier | Effective Date | MA Fee | Prior Authorization Required | Limits |
|----------------|--|---------------|--------------------|--------------------|------------------|------------------------|----------------|---------|------------------------------|--------------|
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 01 | 183 | 12, 22 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 05 | 050, 051 | 12, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 08 | 080 | 12, 31, 32, 50, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 08 | 081 | 12, 31, 32, 72, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 08 | 082 | 12, 49 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 08 | 110 | 49 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 08 | 184 | 12, 57 | | | 3/14/2023 | \$40.00 | No | once per day |

| | | | | | | | | | | |
|-------|--|----|----------|--------------------|--|--|-----------|---------|----|--------------|
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 09 | All | 11, 12, 31, 32, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 10 | 100 | 11, 12, 31, 32, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 24 | All | 11, 31, 32, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 24 | 240, 247 | 12 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 26 | 260, 261 | 12, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 30 | 300 | 12, 65 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 31 | All | 11, 12, 31, 32, 99 | | | 3/14/2023 | \$40.00 | No | once per day |
| 0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation,; booster dose | 33 | 335 | 11, 12, 99 | | | 3/14/2023 | \$40.00 | No | once per day |